Citation Impact
Citing Papers
GSK690693 Delays Tumor Onset and Progression in Genetically Defined Mouse Models Expressing Activated Akt
2010
Synergistic Suppression of Microtubule Dynamics by Discodermolide and Paclitaxel in Non-Small Cell Lung Carcinoma Cells
2004
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells
2002
Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis
2014 Standout
Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo
2018 Standout
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
2016
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY‐142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines
2009
Catalytic Asymmetric Three‐Component Synthesis of Homoallylic Amines
2013 StandoutNobel
Cell mechanics and the cytoskeleton
2010 StandoutNature
Discovery of a novel Raf kinase inhibitor.
2001
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Laulimalide and Paclitaxel: A Comparison of Their Effects on Tubulin Assembly and Their Synergistic Action When Present Simultaneously
2004
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
2012
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo
2010
Drug development from marine natural products
2008 Standout
Detection of Peptides, Proteins, and Drugs That Selectively Interact With Protein Targets
2002 StandoutNobel
Tie2/Angiopoietin-1 Signaling Regulates Hematopoietic Stem Cell Quiescence in the Bone Marrow Niche
2004 Standout
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma
2017
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
2004 Standout
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
2006 Standout
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
2005 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Akt inhibitors in clinical development for the treatment of cancer
2010
Diabetes and cancer
2009
The function of terpene natural products in the natural world
2007 Standout
Distinct Sets of Genetic Alterations in Melanoma
2005 Standout
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Combinations of pacliataxel and vinblastine and their effects on tublin polymerization and cellular cytotoxicity: Characterization of a synergistic schedule
1998
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
2005
Autophagy modulation as a potential therapeutic target for diverse diseases
2012 Standout
Characterization of the Interaction of TZT‐1027, a Potent Antitumor Agent, with Tubulin
2000
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Tachykinin receptor antagonists in clinical trials
2009
Akt signalling in health and disease
2011 Standout
Natural compounds for cancer treatment and prevention
2009 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
The PI3K Pathway in Human Disease
2017 Standout
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
2020 Standout
Phase I Study of Vinorelbine and Docetaxel with Granulocyte Colony-Stimulating Factor Support in the Treatment of Metastatic Breast Cancer
2002
Diabetes and Cancer
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
DNA methylation in the central and efferent limbs of the chemoreflex requires carotid body neural activity
2017 StandoutNobel
Catalytic Asymmetric Three‐Component Synthesis of Homoallylic Amines
2013 StandoutNobel
Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
2004
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.
2003
Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-aminomutase from Taxus chinensis
2014 StandoutNobel
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
1997
The selectivity of protein kinase inhibitors: a further update
2007 Standout
mTOR: a pharmacologic target for autophagy regulation
2015 Standout
Relieving Autophagy and 4EBP1 from Rapamycin Resistance
2011
Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly.
1999
Works of Derek J. Eberwein being referenced
Dominant negative mutants of mitogen-activated protein kinase pathway
2001
Vinorelbine Tartrate and Paclitaxel Combinations: Enhanced Activity Against In Vivo P388 Murine Leukemia Cells
1995
Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
2008
Effect of casopitant, a novel neurokinin -1 (NK-1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of steady-state warfarin
2008